1,442 results on '"Miklos, David"'
Search Results
2. Galectin-3 predicts acute GvHD and overall mortality post reduced intensity allo-HCT: a BMT-CTN biorepository study
3. Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium.
4. CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study
5. Real-World Experience of Cryopreserved Allogeneic Hematopoietic Grafts during the COVID-19 Pandemic: A Single-Center Report.
6. Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity
7. CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity
8. Outcomes of subsequent antilymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7
9. Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma
10. Clinical features of neurotoxicity after CD19 CAR T-cell therapy in mantle cell lymphoma
11. Single-center randomized trial of T-reg graft alone vs T-reg graft plus tacrolimus for the prevention of acute GVHD
12. Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium
13. A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia
14. Genetics of HLA Peptide Presentation and Impact on Outcomes in HLA-Matched Allogeneic Hematopoietic Cell Transplantation
15. Chimeric Antigen Receptor T-Cell Therapy in Aggressive B-Cell Lymphoma
16. Circulating tumor DNA adds specificity to PET after axicabtagene ciloleucel in large B-cell lymphoma
17. Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents
18. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma
19. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.
20. Detection of Aberrant CD58 Expression in a Wide Spectrum of Lymphoma Subtypes: Implications for Treatment Resistance
21. Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma
22. Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy
23. Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy
24. Long-Term Clinical Outcomes and B Cell Immune Reconstitution Following Allo-HCT With Prophylactic, Post-Transplant Rituximab
25. Clinical and Neuroradiological Features of Immune Effector Cell-associated Neurotoxicity Syndrome (ICANS) Following CD19 CAR T-cell Therapy in Mantle Cell Lymphoma (MCL) (S23.007)
26. Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium
27. Targeting PI3Kδ function for amelioration of murine chronic graft-versus-host disease
28. Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients.
29. Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia in the Modern Era
30. Management of post‐autologous transplant relapse in patients with T‐cell lymphomas.
31. Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma
32. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
33. Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B‐cell lymphoma after 2 or more lines of prior therapy
34. Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy
35. Outcomes of subsequent anti-lymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7
36. CAR19 Therapy Drives Expansion of Clonal Hematopoiesis and Associated Cytopenias
37. Neuroaxonal Injury, but Not Astrocyte Injury, Is Associated with CAR T Cell Related Icans.
38. CD19 Antigen Density Down-Regulation at Time of Progression in Large B-Cell Lymphoma Patients Treated with Axicabtagene Ciloleucel
39. Effective Prevention of Steroid-Requiring Chronic Gvhd with B Cell Depletion: A Randomized, Placebo-Controlled Trial
40. Real Time, Point-of-Need Measurement of Blood CD19 CAR-T Vector Load Is Concordant with Standard Ddpcr Method
41. Analysis of PET-CT Derived Radiomic Biomarkers with Efficacy, Safety, and Expansion of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL)
42. Clinical Features of Neurotoxicity Following CD19 CAR T-cell Therapy in Mantle Cell Lymphoma
43. Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma
44. Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia
45. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial
46. Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma
47. CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study
48. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma
49. Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma
50. Specificity of Immunoglobulin High-Throughput Sequencing Minimal Residual Disease Monitoring in Non-Hodgkin Lymphomas
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.